News | December 06, 2024
Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Growth markets revenue increased by 44 YoY to Rs. 812 crore
USFDA completes PAI of Lupin’s biotech facility in Pune
The product is expected to be launched in Q3FY25
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Subscribe To Our Newsletter & Stay Updated
